<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85822">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109250</url>
  </required_header>
  <id_info>
    <org_study_id>D4200R00001</org_study_id>
    <nct_id>NCT02109250</nct_id>
  </id_info>
  <brief_title>CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice</brief_title>
  <acronym>CaprelsaReg</acronym>
  <official_title>CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Belgium: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this registry it is planned to include all Belgian patients diagnosed with aggressive and
      symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who
      have been prescribed Caprelsa® (vandetanib).

      The characteristics of patients receiving Caprelsa® (vandetanib) will be described.
      Therefore real life data regarding demographic characteristics, evolution of the disease,
      RET mutation status, the treatment before, during and after vandetanib, dose and duration of
      treatment with Caprelsa® (vandetanib) and time of progression or death (if applicable) will
      be included.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only</study_design>
  <target_duration>16 Months</target_duration>
  <primary_outcome>
    <measure>The primary objective of this registry is to describe the characteristics of patients who receive Caprelsa® and who are fulfilling the reimbursement criteria.</measure>
    <time_frame>Up to 16 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>In this registry the following real life data will be collected: demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with vandetanib and time of progression or death (if applicable).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>All Belgian Patients With Aggressive, Symptomatic Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer and Taking Caprelsa® Will be Included.</condition>
  <arm_group>
    <arm_group_label>all Belgian patients treated with Caprelsa® (vandetanib)</arm_group_label>
    <description>It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caprelsa</intervention_name>
    <description>Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.</description>
    <arm_group_label>all Belgian patients treated with Caprelsa® (vandetanib)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        It is planned to include all Belgian sites which have patients diagnosed with aggressive
        and symptomatic unresectable locally advanced or metastatic MTC who have been prescribed
        vandetanib and fulfilling the criteria for reimbursement.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

        The subject population that will be observed in this registry, must fulfil all of the
        following criteria:

          1. Provision of subject Informed Consent

          2. Patients diagnosed with aggressive and symptomatic unresectable locally advanced or
             metastatic MTC

          3. Patients who already received a prescription for vandetanib in accordance with the
             scientific leaflet and fulfilling the reimbursement criteria of vandetanib and who
             are currently treated or have been treated with vandetanib 100 mg or 300 mg tablets.

        The prescription of the medicinal product is clearly separated from the decision to
        include the subject in the registry.

        Exclusion criteria Not applicable since patients participating in another study can take
        part in this registry.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lore Decoster, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronique Deschamp</last_name>
    <phone>+32 2 370 48 11</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique du Sud Luxembourg</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Glorieux, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verhoeven Didier, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL St-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelis Frank, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lore Decoster, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Van Belle, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Wallonie</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marie Vandenbulcke, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medullary Thyroid Cancer (MTC) vandetanib caprelsa</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
